

Andrew D Thompson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2666384/publications.pdf>

Version: 2024-02-01

171
papers

6,800
citations

61857

43
h-index

74018

75
g-index

181
all docs

181
docs citations

181
times ranked

6258
citing authors

#	ARTICLE	IF	CITATIONS
1	Cannabidiol for at risk for psychosis youth: A randomized controlled trial. <i>Microbial Biotechnology</i> , 2022, 16, 419-432.	0.9	9
2	The incidence and admission rate for first-episode psychosis in young people before and during the COVID-19 pandemic in Melbourne, Australia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 811-817.	1.3	19
3	The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial. <i>Brain, Behavior, and Immunity</i> , 2022, 99, 147-156.	2.0	2
4	The clinical and functional outcomes of a large naturalistic cohort of young people accessing national early psychosis services. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 1265-1276.	1.3	6
5	Ownership, Use of, and Interest in Digital Mental Health Technologies Among Clinicians and Young People Across a Spectrum of Clinical Care Needs: Cross-sectional Survey. <i>JMIR Mental Health</i> , 2022, 9, e30716.	1.7	18
6	Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class Analysis. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	0.9	2
7	A review of economic evaluations of health care for people at risk of psychosis and for first-episode psychosis. <i>BMC Psychiatry</i> , 2022, 22, 126.	1.1	6
8	Machine learning based prediction and the influence of complement " Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trial. <i>Brain, Behavior, and Immunity</i> , 2022, 103, 50-60.	2.0	4
9	Digital technology for addressing cognitive impairment in recent-onset psychosis: A perspective. <i>Schizophrenia Research: Cognition</i> , 2022, 28, 100247.	0.7	8
10	The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia. <i>Lancet Psychiatry</i> , 2022, 9, 477-486.	3.7	13
11	Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT. <i>Health Technology Assessment</i> , 2022, 26, 1-174.	1.3	16
12	Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosis. <i>Microbial Biotechnology</i> , 2021, 15, 874-881.	0.9	10
13	Improving treatments for psychotic disorders: beyond cognitive behaviour therapy for psychosis. <i>Psychosis</i> , 2021, 13, 78-84.	0.4	14
14	Sleep disturbances and the At Risk Mental State: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2021, 227, 81-91.	1.1	19
15	A certificate in youth psychiatry: meeting the training needs of psychiatrists. <i>Australasian Psychiatry</i> , 2021, 29, 97-100.	0.4	5
16	After the storm, Solar comes out: A new service model for children and adolescent mental health. <i>Microbial Biotechnology</i> , 2021, 15, 731-738.	0.9	13
17	Greater preference for eveningness is associated with negative symptoms in an <sc>ultra-high</sc> risk for psychosis sample. <i>Microbial Biotechnology</i> , 2021, 15, 1793-1798.	0.9	4
18	Implementation lessons from the transition to telehealth during COVID-19: a survey of clinicians and young people from youth mental health services. <i>Psychiatry Research</i> , 2021, 299, 113848.	1.7	91

#	ARTICLE	IF	CITATIONS
19	Cognitive ability and metabolic physical health in first-episode psychosis. <i>Schizophrenia Research: Cognition</i> , 2021, 24, 100194.	0.7	5
20	A novel application of the Lego® Serious Play® methodology in mental health research: Understanding service users' experiences of the 2019 mental health model in the United Kingdom. <i>Microbial Biotechnology</i> , 2021, , .	0.9	0
21	Characterization and prediction of clinical pathways of vulnerability to psychosis through graph signal processing. <i>ELife</i> , 2021, 10, .	2.8	7
22	Patients'™, carers'™ and clinicians'™ attitudes towards alternative terms to describe the at-risk for psychosis state. <i>Schizophrenia Research</i> , 2021, 237, 69-75.	1.1	1
23	The association between migrant status and transition in an ultra-high risk for psychosis population. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 943-952.	1.6	5
24	The need for early intervention for psychosis to persist throughout the COVID-19 pandemic and beyond. <i>Irish Journal of Psychological Medicine</i> , 2021, 38, 214-219.	0.7	14
25	Precursors and correlates of transient and persistent longitudinal profiles of psychotic experiences from late childhood through early adulthood. <i>British Journal of Psychiatry</i> , 2021, , 1-9.	1.7	5
26	Associations between plasma fatty acid concentrations and schizophrenia: a two-sample Mendelian randomisation study. <i>Lancet Psychiatry</i> , 2021, 8, 1062-1070.	3.7	29
27	Testing the Independent and Joint Contribution of Exposure to Neurodevelopmental Adversity and Childhood Trauma to Risk of Psychotic Experiences in Adulthood. <i>Schizophrenia Bulletin</i> , 2021, 47, 776-784.	2.3	5
28	Quality prescribing in early psychosis: key pharmacotherapy principles. <i>Australasian Psychiatry</i> , 2021, , 103985622110546.	0.4	2
29	A Computational Analysis of Abnormal Belief Updating Processes and Their Association With Psychotic Experiences and Childhood Trauma in a UK Birth Cohort. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, , .	1.1	5
30	Insulin resistance and obesity, and their association with depression in relatively young people: findings from a large UK birth cohort. <i>Psychological Medicine</i> , 2020, 50, 556-565.	2.7	25
31	Co-designing a virtual world with young people to deliver social cognition therapy in early psychosis. <i>Microbial Biotechnology</i> , 2020, 14, 37-43.	0.9	29
32	The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis. <i>Biological Psychiatry</i> , 2020, 87, 243-252.	0.7	48
33	Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis. <i>Schizophrenia Research</i> , 2020, 226, 52-60.	1.1	8
34	The prevalence of personality disorders in the community: a global systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2020, 216, 69-78.	1.7	141
35	Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people. <i>Schizophrenia Research</i> , 2020, 226, 44-51.	1.1	27
36	Experiences and satisfaction of children, young people and their parents with alternative mental health models to inpatient settings: a systematic review. <i>European Child and Adolescent Psychiatry</i> , 2020, 29, 1621-1633.	2.8	18

#	ARTICLE	IF	CITATIONS
37	Psychopathological outcomes of adolescent borderline personality disorder symptoms. Australian and New Zealand Journal of Psychiatry, 2020, 54, 308-317.	1.3	22
38	Evidence for preventive treatments in young patients at clinical high risk of psychosis: the need for context. Lancet Psychiatry, the, 2020, 7, 378-380.	3.7	9
39	Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomes. Schizophrenia Research, 2020, 216, 255-261.	1.1	8
40	A Population-Based Cohort Study Examining the Incidence and Impact of Psychotic Experiences From Childhood to Adulthood, and Prediction of Psychotic Disorder. American Journal of Psychiatry, 2020, 177, 308-317.	4.0	98
41	Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial. Behaviour Research and Therapy, 2020, 124, 103527.	1.6	16
42	T34. THE IMPACT OF ANTIDEPRESSANT USE ON THE TRANSITION TO PSYCHOSIS RATE IN THE NEURAPRO TRIAL. Schizophrenia Bulletin, 2020, 46, S244-S245.	2.3	0
43	S134. INCIDENCE, IMPACT AND TRAJECTORIES OF PSYCHOTIC EXPERIENCES FROM CHILDHOOD TO ADULTHOOD, AND PREDICTION OF PSYCHOTIC DISORDER. Schizophrenia Bulletin, 2020, 46, S86-S86.	2.3	0
44	Does cortical brain morphology act as a mediator between childhood trauma and transition to psychosis in young individuals at ultra-high risk?. Schizophrenia Research, 2020, 224, 116-125.	1.1	9
45	Omega-3 and Omega-6 fatty acids and risk of psychotic outcomes in the ALSPAC birth cohort. Schizophrenia Research, 2020, 224, 108-115.	1.1	7
46	The potential impact of COVID-19 on psychosis: A rapid review of contemporary epidemic and pandemic research. Schizophrenia Research, 2020, 222, 79-87.	1.1	272
47	Do schizotypal or borderline personality disorders predict onset of psychotic disorder or persistent attenuated psychotic symptoms in patients at high clinical risk?. Schizophrenia Research, 2020, 220, 275-277.	1.1	3
48	Psychosocial Intervention With or Without Antipsychotic Medication for First-Episode Psychosis: A Randomized Noninferiority Clinical Trial. Schizophrenia Bulletin Open, 2020, 1, .	0.9	45
49	Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial. Schizophrenia Research, 2020, 218, 48-54.	1.1	8
50	Commentary: Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence). Frontiers in Psychiatry, 2020, 11, 488.	1.3	3
51	Participatory approaches, local stakeholders and cultural relevance facilitate an impactful community-based project in Uganda. Health Promotion International, 2020, 35, 1353-1368.	0.9	10
52	Society and risk of psychosis. , 2020, , 289-303.		0
53	A Feasibility and Acceptability Trial of Social Cognitive Therapy in Early Psychosis Delivered Through a Virtual World: The VEEP Study. Frontiers in Psychiatry, 2020, 11, 219.	1.3	22
54	Phylogenetic Analysis Indicates a Longer Term Presence of the Globally Distributed H58 Haplotype of Salmonella Typhi in Southern India. Clinical Infectious Diseases, 2020, 71, 1856-1863.	2.9	21

#	ARTICLE	IF	CITATIONS
55	Early Signs Monitoring to Prevent Relapse in Psychosis and Promote Well-Being, Engagement, and Recovery: Protocol for a Feasibility Cluster Randomized Controlled Trial Harnessing Mobile Phone Technology Blended With Peer Support. <i>JMIR Research Protocols</i> , 2020, 9, e15058.	0.5	24
56	Virtual reality as a clinical tool in mental health research and practice. <i>Dialogues in Clinical Neuroscience</i> , 2020, 22, 169-177.	1.8	98
57	Does reason for referral to an ultra-high risk clinic predict transition to psychosis?. <i>Microbial Biotechnology</i> , 2019, 13, 318-321.	0.9	7
58	Dysglycaemia, Inflammation and Psychosis: Findings From the UK ALSPAC Birth Cohort. <i>Schizophrenia Bulletin</i> , 2019, 45, 330-338.	2.3	42
59	Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial. <i>Frontiers in Psychiatry</i> , 2019, 10, 393.	1.3	22
60	The relationship between childhood trauma and clinical characteristics in ultra-high risk for psychosis youth. <i>Psychosis</i> , 2019, 11, 28-41.	0.4	6
61	Short-term outcome of first episode delusional disorder in an early intervention population. <i>Schizophrenia Research</i> , 2019, 204, 72-79.	1.1	4
62	Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial. <i>Schizophrenia Research</i> , 2019, 206, 67-74.	1.1	46
63	Association of Trauma Type, Age of Exposure, and Frequency in Childhood and Adolescence With Psychotic Experiences in Early Adulthood. <i>JAMA Psychiatry</i> , 2019, 76, 79.	6.0	162
64	The use of participatory visual methods with community health workers: A systematic scoping review of the literature. <i>Global Public Health</i> , 2019, 14, 722-736.	1.0	12
65	Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low risk of self-harm or aggression. Study protocol and baseline characteristics of participants. <i>Microbial Biotechnology</i> , 2019, 13, 953-960.	0.9	19
66	Perceptual abnormalities in an ultra-high risk for psychosis population relationship to trauma and co-morbid disorder. <i>Microbial Biotechnology</i> , 2019, 13, 231-240.	0.9	5
67	Research and practice for ultra-high risk for psychosis: A national survey of early intervention in psychosis services in England. <i>Microbial Biotechnology</i> , 2019, 13, 47-52.	0.9	15
68	F252. SERVICE PROVISION FOR ULTRA-HIGH RISK FOR PSYCHOSIS: IMPLEMENTATION OF CLINICAL GUIDELINES IN ENGLAND. <i>Schizophrenia Bulletin</i> , 2018, 44, S321-S321.	2.3	0
69	The importance of clinical observation: A case of subtle tardive dyskinesia with paliperidone palmitate. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 496-497.	1.3	2
70	The clue in the face: An unusual first episode psychosis presentation. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 293-294.	1.3	1
71	Should we be using digital technologies in the treatment of psychotic disorders?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 225-226.	1.3	6
72	The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo. <i>Schizophrenia Research</i> , 2018, 195, 543-548.	1.1	28

#	ARTICLE	IF	CITATIONS
73	The views of early intervention service staff on the treatment of first episode bipolar disorder. <i>International Journal of Psychiatry in Clinical Practice</i> , 2018, 22, 225-231.	1.2	4
74	F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS. <i>Schizophrenia Bulletin</i> , 2018, 44, S228-S228.	2.3	1
75	S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING. <i>Schizophrenia Bulletin</i> , 2018, 44, S378-S379.	2.3	1
76	Granular Cell Tumor Imaging Using Optical Coherence Tomography. <i>Biomedical Engineering and Computational Biology</i> , 2018, 9, 117959721879025.	0.8	11
77	NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disordersâ€”medium-term follow-up and clinical course. NPJ <i>Schizophrenia</i> , 2018, 4, 11.	2.0	41
78	Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review. <i>BJPsych Open</i> , 2018, 4, 215-225.	0.3	29
79	Dynamic prediction of transition to psychosis using joint modelling. <i>Schizophrenia Research</i> , 2018, 202, 333-340.	1.1	18
80	An fMRI study of theory of mind in individuals with first episode psychosis. <i>Psychiatry Research - Neuroimaging</i> , 2018, 281, 1-11.	0.9	10
81	Examining the association between social cognition and functioning in individuals at ultra-high risk for psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 83-92.	1.3	29
82	NEURAPROâ€™s study protocol: a multicentre randomized controlled trial of omegaâ€”3 fatty acids and cognitiveâ€”behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. <i>Microbial Biotechnology</i> , 2017, 11, 418-428.	0.9	55
83	The longitudinal association between external locus of control, social cognition and adolescent psychopathology. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2017, 52, 643-655.	1.6	34
84	Effect of Î‰-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders. <i>JAMA Psychiatry</i> , 2017, 74, 19.	6.0	216
85	Long-term employment among people at ultra-high risk for psychosis. <i>Schizophrenia Research</i> , 2017, 184, 26-31.	1.1	28
86	The sleep phenotype of Borderline Personality Disorder: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 73, 48-67.	2.9	40
87	Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis. <i>Psychotherapy and Psychosomatics</i> , 2017, 86, 292-299.	4.0	20
88	The access and waiting-time standard for first-episode psychosis: an opportunity for identification and treatment of psychosis risk states?. <i>BJPsych Bulletin</i> , 2017, 41, 1-2.	0.7	4
89	Response to letters by Baethge et al. and Martino et al.. <i>International Journal of Bipolar Disorders</i> , 2017, 5, 21.	0.8	0
90	Stati mentali a rischio di psicosi: identificazione e strategie attuali di trattamento [translation of â€œAt-risk mental state for psychosis: identification and current treatment approachesâ€”by Dr. Giulia Rioli]. <i>BJ Psych Advances</i> , 2016, 22, .	0.5	0

#	ARTICLE	IF	CITATIONS
91	Views of early psychosis clinicians on discontinuation of antipsychotic medication following symptom remission in first episode psychosis. <i>Microbial Biotechnology</i> , 2016, 10, 355-361.	0.9	27
92	School mobility during childhood predicts psychotic symptoms in late adolescence. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2016, 57, 957-966.	3.1	18
93	Fifteen years on "early intervention for a new generation. <i>British Journal of Psychiatry</i> , 2016, 209, 186-188.	1.7	31
94	A longitudinal investigation of childhood communication ability and adolescent psychotic experiences in a community sample. <i>Schizophrenia Research</i> , 2016, 173, 54-61.	1.1	15
95	At-risk mental state for psychosis: identification and current treatment approaches. <i>BJ Psych Advances</i> , 2016, 22, 186-193.	0.5	11
96	Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era. <i>CNS Drugs</i> , 2016, 30, 357-368.	2.7	67
97	A systematic review of the neurobiological underpinnings of borderline personality disorder (BPD) in childhood and adolescence. <i>Reviews in the Neurosciences</i> , 2016, 27, 827-847.	1.4	28
98	Short-term outcome of substance-induced psychotic disorder in a large UK first episode psychosis cohort. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 321-328.	2.2	15
99	Is treatment for bipolar disorder more effective earlier in illness course? A comprehensive literature review. <i>International Journal of Bipolar Disorders</i> , 2016, 4, 19.	0.8	54
100	Effectiveness of antipsychotics used in first-episode psychosis: a naturalistic cohort study. <i>BJPsych Open</i> , 2016, 2, 323-329.	0.3	20
101	The aetiological and psychopathological validity of borderline personality disorder in youth: A systematic review and meta-analysis. <i>Clinical Psychology Review</i> , 2016, 44, 13-24.	6.0	98
102	Are UHR patients who present with hallucinations alone at lower risk of transition to psychosis?. <i>Psychiatry Research</i> , 2016, 235, 177-196.	1.7	12
103	Do affective or dissociative symptoms mediate the association between childhood sexual trauma and transition to psychosis in an ultra-high risk cohort?. <i>Psychiatry Research</i> , 2016, 236, 182-185.	1.7	20
104	Clinical and psychosocial outcomes of borderline personality disorder in childhood and adolescence: a systematic review. <i>Psychological Medicine</i> , 2015, 45, 2237-2251.	2.7	68
105	Childhood maltreatment and transition to psychotic disorder independently predict long-term functioning in young people at ultra-high risk for psychosis. <i>Psychological Medicine</i> , 2015, 45, 3453-3465.	2.7	51
106	Childhood sleep disturbance and risk of psychotic experiences at 18: UK birth cohort. <i>British Journal of Psychiatry</i> , 2015, 207, 23-29.	1.7	50
107	Neighbourhood characteristics and the rate of identification of young people at ultra-high risk for psychosis. <i>Schizophrenia Research</i> , 2015, 169, 214-216.	1.1	14
108	Adult attention deficit hyperactivity symptoms and psychosis: Epidemiological evidence from a population survey in England. <i>Psychiatry Research</i> , 2015, 229, 49-56.	1.7	21

#	ARTICLE	IF	CITATIONS
109	Social environmental risk factors for transition to psychosis in an Ultra-High Risk population. <i>Schizophrenia Research</i> , 2015, 161, 150-155.	1.1	23
110	Behavioral and Psychiatric Symptoms in Prion Disease. <i>American Journal of Psychiatry</i> , 2014, 171, 265-274.	4.0	38
111	Emotion recognition as a predictor of transition to a psychotic disorder in ultra-high risk participants. <i>Schizophrenia Research</i> , 2014, 153, 25-31.	1.1	51
112	Sexual Trauma Increases the Risk of Developing Psychosis in an Ultra High-Risk "Prodromal" Population. <i>Schizophrenia Bulletin</i> , 2014, 40, 697-706.	2.3	108
113	HISTORY OF TRAUMA IN THE ULTRA HIGH RISK FOR PSYCHOSIS POPULATION: FINDINGS FROM THE PACE CLINIC. <i>Schizophrenia Research</i> , 2014, 153, S43.	1.1	0
114	Childhood Parasomnias and Psychotic Experiences at Age 12 Years in a United Kingdom Birth Cohort. <i>Sleep</i> , 2014, 37, 475-482.	0.6	66
115	Not all first-episode psychosis is the same: preliminary evidence of greater basic self-disturbance in schizophrenia spectrum cases. <i>Microbial Biotechnology</i> , 2013, 7, 200-204.	0.9	55
116	Psychotic experiences and social functioning: a longitudinal study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2013, 48, 1053-1065.	1.6	9
117	History of trauma and the association with baseline symptoms in an Ultra-High Risk for psychosis cohort. <i>Psychiatry Research</i> , 2013, 210, 75-81.	1.7	41
118	Externalized attributional bias in the Ultra High Risk (UHR) for psychosis population. <i>Psychiatry Research</i> , 2013, 206, 200-205.	1.7	37
119	Affect recognition and functioning in putatively prodromal individuals. <i>Schizophrenia Research</i> , 2013, 147, 404-405.	1.1	10
120	Social cognition training as an intervention for improving functional outcome in first-episode psychosis: a feasibility study. <i>Microbial Biotechnology</i> , 2013, 7, 421-426.	0.9	42
121	Long-term Follow-up of a Group at Ultra High Risk ("Prodromal") for Psychosis. <i>JAMA Psychiatry</i> , 2013, 70, 793.	6.0	373
122	Does specific psychopathology predict development of psychosis in ultra high-risk (UHR) patients?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 380-390.	1.3	22
123	Is basic self-disturbance in ultra-high risk for psychosis ("prodromal") patients associated with borderline personality pathology?. <i>Microbial Biotechnology</i> , 2013, 7, 306-310.	0.9	34
124	Omega-3 Fatty Acid Supplementation in Adolescents with Borderline Personality Disorder and Ultra-High Risk Criteria for Psychosis: A Post Hoc Subgroup Analysis of a Double-Blind, Randomized Controlled Trial. <i>Canadian Journal of Psychiatry</i> , 2013, 58, 402-408.	0.9	55
125	Randomized Controlled Trial of Interventions for Young People at Ultra-High Risk of Psychosis. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 349-356.	1.1	128
126	Basic Self-Disturbance Predicts Psychosis Onset in the Ultra High Risk for Psychosis "Prodromal" Population. <i>Schizophrenia Bulletin</i> , 2012, 38, 1277-1287.	2.3	236

#	ARTICLE	IF	CITATIONS
127	Is there a gap between recommended and "real world"™ practice in the management of depression in young people? A medical file audit of practice. <i>BMC Health Services Research</i> , 2012, 12, 178.	0.9	19
128	The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: Summaries of oral sessions. <i>Schizophrenia Research</i> , 2012, 141, e1-e24.	1.1	8
129	Social cognition in clinical "at risk" for psychosis and first episode psychosis populations. <i>Schizophrenia Research</i> , 2012, 141, 204-209.	1.1	96
130	Devolution and Patient Choice: Policy Rhetoric versus Experience in Practice. <i>Social Policy and Administration</i> , 2012, 46, 199-218.	2.1	16
131	Non-expert clinicians' detection of autistic traits among attenders of a youth mental health service. <i>Microbial Biotechnology</i> , 2012, 6, 83-86.	0.9	9
132	Facial and vocal affect perception in people at ultra-high risk of psychosis, first episode schizophrenia and healthy controls. <i>Microbial Biotechnology</i> , 2012, 6, 450-454.	0.9	57
133	Borderline personality features and development of psychosis in an "Ultra High Risk"™ (UHR) population: a case control study. <i>Microbial Biotechnology</i> , 2012, 6, 247-255.	0.9	27
134	Association between locus of control in childhood and psychotic symptoms in early adolescence: Results from a large birth cohort. <i>Cognitive Neuropsychiatry</i> , 2011, 16, 385-402.	0.7	40
135	The relationship between coping and subclinical psychotic experiences in adolescents from the general population " a longitudinal study. <i>Psychological Medicine</i> , 2011, 41, 2535-2546.	2.7	63
136	Predictive validity of clinical variables in the "at risk" for psychosis population: International comparison with results from the North American Prodrome Longitudinal Study. <i>Schizophrenia Research</i> , 2011, 126, 51-57.	1.1	79
137	The Comprehensive Assessment of At-Risk Mental States: From mapping the onset to mapping the structure. <i>Schizophrenia Research</i> , 2011, 127, 107-114.	1.1	45
138	Social cognition deficits and the "ultra high risk"™ for psychosis population: a review of literature. <i>Microbial Biotechnology</i> , 2011, 5, 192-202.	0.9	68
139	Using internet enabled mobile devices and social networking technologies to promote exercise as an intervention for young first episode psychosis patients. <i>BMC Psychiatry</i> , 2011, 11, 80.	1.1	22
140	What are Specialist Mental Health Clinician Attitudes to Guideline Recommendations for the Treatment of Depression in Young People?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 993-1001.	1.3	20
141	Increased adolescent mortality in the year after a psychiatric admission. <i>Evidence-Based Mental Health</i> , 2011, 14, 43-43.	2.2	0
142	Targeted Intervention to Improve Monitoring of Antipsychotic-Induced Weight Gain and Metabolic Disturbance in First Episode Psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 740-748.	1.3	28
143	Prevalence of Autism Spectrum Conditions in a Youth Mental Health Service. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 426-426.	1.3	3
144	Childhood facial emotion recognition and psychosis-like symptoms in a nonclinical population at 12 years of age: Results from the ALSPAC birth cohort. <i>Cognitive Neuropsychiatry</i> , 2011, 16, 136-157.	0.7	17

#	ARTICLE	IF	CITATIONS
145	Interventions Targeting Social and Vocational Dysfunction in Individuals with a Schizophrenia Spectrum Disorder. , 2011, , 173-207.		2
146	Randomized Controlled Trial of Interventions for Young People at Ultra High Risk for Psychosis. Journal of Clinical Psychiatry, 2011, 72, 430-440.	1.1	128
147	A preliminary evaluation of the validity of at-risk criteria for bipolar disorders in help-seeking adolescents and young adults. Journal of Affective Disorders, 2010, 127, 316-320.	2.0	104
148	Experience of trauma and conversion to psychosis in an ultraâ€highâ€risk (prodromal) group. Acta Psychiatrica Scandinavica, 2010, 121, 377-384.	2.2	154
149	Effectiveness of a cognitive behavioural workbook for changing beliefs about antipsychotic polypharmacy: analysis from a cluster randomized controlled trial. Journal of Evaluation in Clinical Practice, 2010, 16, 520-528.	0.9	6
150	Promoting Physical Health In Youth Mental Health Services: Ensuring Routine Monitoring of Weight and Metabolic Indices in a First Episode Psychosis Clinic. Australasian Psychiatry, 2010, 18, 451-455.	0.4	32
151	EXPERIENCE OF TRAUMA AND CONVERSION TO PSYCHOTIC DISORDER IN INDIVIDUALS AT ULTRA HIGH RISK ("PRODROMAL") OF DEVELOPING FIRST EPISODE PSYCHOSIS. Schizophrenia Research, 2010, 117, 529-530.	1.1	0
152	Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophrenia Research, 2010, 119, 1-10.	1.1	97
153	The psychosis threshold in Ultra High Risk (prodromal) research: Is it valid?. Schizophrenia Research, 2010, 120, 1-6.	1.1	138
154	Should a â€œRisk Syndrome for Psychosisâ€be included in the DSMV?. Schizophrenia Research, 2010, 120, 7-15.	1.1	78
155	Psychotic symptoms with sexual content in the â€œultra high riskâ€for psychosis population: Frequency and association with sexual trauma. Psychiatry Research, 2010, 177, 84-91.	1.7	57
156	Association of measures of fetal and childhood growth with non-clinical psychotic symptoms in 12-year-olds: the ALSPAC cohort. British Journal of Psychiatry, 2009, 194, 521-526.	1.7	30
157	Investigating whether adverse prenatal and perinatal events are associated with non-clinical psychotic symptoms at age 12 years in the ALSPAC birth cohort. Psychological Medicine, 2009, 39, 1457-1467.	2.7	102
158	Pseudoneurotic Schizophrenia Revisited. Australian and New Zealand Journal of Psychiatry, 2009, 43, 873-876.	1.3	7
159	Prospective Study of Peer Victimization in Childhood and Psychotic Symptoms in a Nonclinical Population at Age 12 Years. Archives of General Psychiatry, 2009, 66, 527.	13.8	316
160	A disturbed sense of self in the psychosis prodrome: Linking phenomenology and neurobiology. Neuroscience and Biobehavioral Reviews, 2009, 33, 807-817.	2.9	129
161	Does disturbance of self underlie social cognition deficits in schizophrenia and other psychotic disorders?. Microbial Biotechnology, 2009, 3, 83-93.	0.9	47
162	Maternal tobacco, cannabis and alcohol use during pregnancy and risk of adolescent psychotic symptoms in offspring. British Journal of Psychiatry, 2009, 195, 294-300.	1.7	95

#	ARTICLE	IF	CITATIONS
163	Investigating if psychosis-like symptoms (PLIKS) are associated with family history of schizophrenia or paternal age in the ALSPAC birth cohort. Schizophrenia Research, 2008, 104, 279-286.	1.1	62
164	Frequency of psychosis-like symptoms in a non-clinical population of 12 year olds: Results from the Alspac birth cohort. European Psychiatry, 2008, 23, S282.	0.1	8
165	The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards—A cluster randomized controlled trial. Psychological Medicine, 2008, 38, 705-715.	2.7	64
166	IQ and non-clinical psychotic symptoms in 12-year-olds: results from the ALSPAC birth cohort. British Journal of Psychiatry, 2008, 193, 185-191.	1.7	233
167	NICE guidelines on treating schizophrenia — audit. Psychiatric Bulletin, 2008, 32, 75-75.	0.3	2
168	Bridging the gap between the university and the NHS: health services research in psychiatry. Psychiatric Bulletin, 2008, 32, 146-149.	0.3	0
169	An audit of clinical practice in an ACT team against NICE guidelines in schizophrenia. Journal of Psychiatric Intensive Care, 2007, 3, .	0.2	0
170	Reply: Late-Onset Neutropenia with Clozapine. Canadian Journal of Psychiatry, 2006, 51, 125-126.	0.9	0
171	Patterns of hospital admission for adult psychiatric illness in England: analysis of Hospital Episode Statistics data. British Journal of Psychiatry, 2004, 185, 334-341.	1.7	114